Study of Rilpivirine use in HIV-Infected People at Krabi Hospital
Keywords:
Efavirenz, Rilpivirine, Lopinavir/ ritonavir, HIVAbstract
Background: Rilpivirine is a second-generation non-nucleoside reverse transcriptase inhibitors (NNRTIs) that has fewer side effects than other NNRTIs, especially Efavirenz and is easier to administer than Lopinavir/ ritonavir. There is also a cheaper price per day than other drugs.
Objective: This study was to study the effectiveness and cost reduce of Rilpivirine antiretroviral therapy.
Methods: This retrospective study was done at Krabi Hospital by collecting data from study groups using Rilpivirine instead of Efavirenz (EFV) or Lopinavir/ ritonavir (LPV/ r) by evaluating the treatment of HIV viral load after taking Rilpivirine for not less than 24 weeks.
Results: All the study group found that HIV viral load were less than 40 copies/ml and no severe adverse reactions were reported. In addition, the cost can be reduced by 1049.96 baht per person per month.
Conclusion: Changes in treatment from Efavirenz, Lopinavir/ ritonavir to Rilpivirine do not reduce the effectiveness of the treatment, side effects decreased and the cost of medication also decreased.
References
Fauci AS, Folkers GK, Lane HC. Human Immuno-deficiency Virus Disease: AIDS and related disorders. In: Kasper D, Fauci A, Hauser S,Longo D, Jameson JL, Loscalzo J, editors. Harrison’s principles of internal medicine. 19th ed. NY: McGraw-Hill Education; 2015. p. 1215-85.
Thai MoH/NAC/UNAIDS ‘AIDS Zero Portal: Data use tool’ (accessed November 2019)
Brookie BM, Miguel G. Efavirenz – Still First Line King. Expert Opin Drug Metab Toxicol 2008; 4: 965–72.
Behrens G, Rijnders B, Nelson M, Orkin C, Cohen C, Mills A, et al. Rilpivirine Versus Efavirenz with Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-Naïve HIV-1–Infected Patients with HIV-1 RNA ≤100,000 Copies/mL: Week 96 Pooled ECHO/THRIVE Subanalysis. AIDS Patient Care STDS 2014; 28: 168–75.
Department of Disease Control. Thailand National Guideline on HIV/AIDS Treatment and Prevention 2014. 1st ed. Bangkok: ACFT; 2014. p. 65-167.
Department of Disease Control. Thailand National Guideline on HIV/AIDS Treatment and Prevention 2017.1st ed. Bangkok: ACFT; 2017. p. 67-176.
Mills AM, Cohen C, Dejesus E, Brinson C, Williams S, Yale K L, et al. Efficacy and safety 48 weeks after switching from efavirenz to Rilpivirine using emtricitabine/tenofovir disoproxil fumarate based single-tablet regimens. HIV Clin Trials 2013; 14: 216-23.
Jantarabenjakul W, Anugulruengkitt S, Kasipong N.Pharmacokinetics of Rilpivirine and 24-week Outcomes after Switching from Efavirenz in Virologically Suppressed HIV-1-infected Adolescents. Antivir Ther 2018; 2:259-65.
Somton P, Sutananun W. Efficacy and Lipid Profile Change after Switching from Efavirenz to Rilpivirine, Journal of Bamrasnaradura Infectious Diseases Institute 2018; 12:105-11.
Melikian L G, Rhee Y S, Varghese V, Porter D, White K, Taylor J, et al, Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI) Cross-Resistance: Implications for Preclinical Evaluation of Novel NNRTIs and Clinical Genotypic Resistance Testing. J Antimicrob Chemother 2014; 69:12-20.
Bunupuradah T, Ananworanich J, Chetchotisakd P, Kantipong P, Jirajariyavej S, Sirivichayakul S, et al. Etravirine and Rilpivirine Resistance in HIV-1 Subtype CRF01_AE-infected Adults Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Regimens. Antivir Ther 2011; 16:1113-21.
Teeranaipong P, Sirivichayakul S, Mekprasan S, Ohata PJ, Avihingsanon A, Ruxrungtham K, et al. Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study. PLoS One 2016; 11: e0154221.
Llibre J M, Poveda E, Anta L, Blanco J L, Alvarez M, PérezElías M J, et al. Rilpivirine Resistance Mutations in HIV Patients Failing Non-Nucleoside Reverse Transcriptase Inhibitor-Based Therapies. AIDS 2013;27:81-5.
Gupta RK, Gregson J, Parkin N, Haile-Selassie H, Tanuri A, Forero LA, et al. HIV-1 drug resistance before initiation or re-initiation of first-line antiretroviral therapy in low-income and middle-income countries: a systematic review and meta-regression analysis, Lancet Infect Dis 2017;18: 346–55.
Ford N, Lee J, Andrieux-Meyer I, Calmy A. Safety, efficacy, and pharmacokinetics of rilpivirine: systematic review with an emphasis on resource-limited settings, HIV/AIDS – Research and Palliative Care 2011;3: 35–44.
LiverTox: Clinical and Research Information on DrugInduced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases; 2012-. Rilpivirine. [Updated 2017 Feb 20].Available on : https://www.ncbi.nlm. nih.gov/books/NBK548514.
Downloads
Published
How to Cite
Issue
Section
License
บทความที่ได้รับการตีพิมพ์เป็นลิขสิทธิ์ของกรมการแพทย์ กระทรวงสาธารณสุข
ข้อความและข้อคิดเห็นต่างๆ เป็นของผู้เขียนบทความ ไม่ใช่ความเห็นของกองบรรณาธิการหรือของวารสารกรมการแพทย์
